Follow
Henrik Zetterberg
Henrik Zetterberg
Sahlgrenska
Verified email at clinchem.gu.se
Title
Cited by
Cited by
Year
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
K Blennow, H Hampel, M Weiner, H Zetterberg
Nature Reviews Neurology 6 (3), 131-144, 2010
21282010
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O Hansson, H Zetterberg, P Buchhave, E Londos, K Blennow, L Minthon
The Lancet Neurology 5 (3), 228-234, 2006
21092006
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
B Olsson, R Lautner, U Andreasson, A Öhrfelt, E Portelius, M Bjerke, ...
The Lancet Neurology 15 (7), 673-684, 2016
18872016
Defeating Alzheimer's disease and other dementias: a priority for European science and society
B Winblad, P Amouyel, S Andrieu, C Ballard, C Brayne, H Brodaty, ...
The Lancet Neurology 15 (5), 455-532, 2016
17492016
Gut microbiome alterations in Alzheimer’s disease
NM Vogt, RL Kerby, KA Dill-McFarland, SJ Harding, AP Merluzzi, ...
Scientific reports 7 (1), 13537, 2017
15572017
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis
WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms, P Scheltens, ...
Jama 313 (19), 1924-1938, 2015
14722015
Neurofilaments as biomarkers in neurological disorders
M Khalil, CE Teunissen, M Otto, F Piehl, MP Sormani, T Gattringer, ...
Nature Reviews Neurology 14 (10), 577-589, 2018
14352018
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
N Mattsson, H Zetterberg, O Hansson, N Andreasen, L Parnetti, ...
Jama 302 (4), 385-393, 2009
14262009
Clearance systems in the brain—implications for Alzheimer disease
JM Tarasoff-Conway, RO Carare, RS Osorio, L Glodzik, T Butler, ...
Nature reviews neurology 11 (8), 457-470, 2015
14252015
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
G Disanto, C Barro, P Benkert, Y Naegelin, S Schädelin, A Giardiello, ...
Annals of neurology 81 (6), 857-870, 2017
9432017
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
L Lannfelt, K Blennow, H Zetterberg, S Batsman, D Ames, J Harrison, ...
The Lancet Neurology 7 (9), 779-786, 2008
8392008
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
TK Karikari, TA Pascoal, NJ Ashton, S Janelidze, AL Benedet, ...
The Lancet Neurology 19 (5), 422-433, 2020
7982020
Neurofilament light chain as a biomarker in neurological disorders
L Gaetani, K Blennow, P Calabresi, M Di Filippo, L Parnetti, H Zetterberg
Journal of Neurology, Neurosurgery & Psychiatry 90 (8), 870-881, 2019
7972019
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
H Hampel, R Frank, K Broich, SJ Teipel, RG Katz, J Hardy, K Herholz, ...
Nature reviews Drug discovery 9 (7), 560-574, 2010
7972010
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
S Janelidze, N Mattsson, S Palmqvist, R Smith, TG Beach, GE Serrano, ...
Nature medicine 26 (3), 379-386, 2020
7942020
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
N Mattsson, U Andreasson, H Zetterberg, K Blennow, ...
JAMA neurology 74 (5), 557-566, 2017
7912017
The neuropathology and neurobiology of traumatic brain injury
K Blennow, J Hardy, H Zetterberg
Neuron 76 (5), 886-899, 2012
7792012
Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders
S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg, F Lopera, E Stomrud, ...
Jama 324 (8), 772-781, 2020
7702020
Biomarkers for Alzheimer's disease: current status and prospects for the future
K Blennow, H Zetterberg
Journal of internal medicine 284 (6), 643-663, 2018
7582018
Cerebrospinal fluid levels ofβ-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia
P Buchhave, L Minthon, H Zetterberg, ÅK Wallin, K Blennow, O Hansson
Archives of general psychiatry 69 (1), 98-106, 2012
7562012
The system can't perform the operation now. Try again later.
Articles 1–20